BERKELEY, Calif.–(BUSINESS WIRE)–Sep 28, 2021–
Acrigen Biosciences, Inc. (‘Acrigen’), an early-stage biotechnology company developing precision gene editing technology and genetic medicines, today announced its seed financing round led by Red Tree Venture Capital with participation from Alexandria Venture Investments, the Berkeley Catalyst Fund, Dolby Family Ventures, and biotechnology entrepreneur investors. The capital will be used to advance Acrigen’s therapeutic pipeline toward the clini
https://apnews.com/press-release/business-wire/business-technology-science-genetics-berkeley-372a0602f96b42d38342c480bf36a596
